Antitumor activity of immunoconjugates composed of boanmycin and monoclonal antibody

Chin Med Sci J. 1994 Jun;9(2):75-80.


Boanmycin (bleomycin A6, BM), an antitumor antibiotic, was conjugated to monoclonal antibodies including R19, H111 and CCT2. The immunoconjugates exhibited selective cytotoxicity to related target cells including cecum cancer Hce-8693 cells, liver cancer BEL-7402 cells and leukemia CEM cells. They were highly effective against related human tumor xenografts in nude mice, and the inhibition rates by the conjugates were much higher than those by free BM. The inhibition rate by R19-BM conjugate against human cecum cancer xenografts reached 90%. BY immunoelectron microscopy, CCT2-BM conjugate showed specific binding and internalization in leukemia CEM cells. The results indicate that boanmycin-monoclonal antibody immunoconjugates are highly active both in vitro and in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology*
  • Adenocarcinoma / therapy
  • Animals
  • Antibiotics, Antineoplastic / pharmacology*
  • Antibiotics, Antineoplastic / therapeutic use
  • Antibodies, Monoclonal
  • Bleomycin / pharmacology*
  • Bleomycin / therapeutic use
  • Carcinoma, Hepatocellular / pathology
  • Cecal Neoplasms / pathology*
  • Cecal Neoplasms / therapy
  • Humans
  • Immunotoxins / pharmacology*
  • Immunotoxins / therapeutic use
  • Liver Neoplasms / pathology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Transplantation
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Tumor Cells, Cultured / drug effects


  • Antibiotics, Antineoplastic
  • Antibodies, Monoclonal
  • Immunotoxins
  • bleomycin A6
  • Bleomycin